Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
University of Ulm
Young Adult Survivors United
Scripps Translational Science Institute
CARGO Therapeutics
Celgene
Strata Oncology
Pfizer
Zhejiang DTRM Biopharma
Takeda
Celgene
Taiho Oncology, Inc.
Pfizer
Altor BioScience
Centre Hospitalier Henri Duffaut - Avignon
University of Virginia
New Mexico Cancer Research Alliance
Sumitomo Pharma America, Inc.
Asana BioSciences
Seagen Inc.
Bristol-Myers Squibb
AbbVie
AbbVie
Molecular Templates, Inc.
GlaxoSmithKline
miRagen Therapeutics, Inc.
Swiss Cancer Institute
AbbVie
PharmaMar
miRagen Therapeutics, Inc.
Sunesis Pharmaceuticals
University of California, San Diego
University of Oklahoma
GlaxoSmithKline
University of Minnesota
Masonic Cancer Center, University of Minnesota
AHS Cancer Control Alberta
Novartis
Seagen Inc.
Gilead Sciences
Seagen Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vanderbilt-Ingram Cancer Center
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
Baylor College of Medicine
Bayer
Exelixis
New Mexico Cancer Research Alliance
University of South Florida
City of Hope Medical Center